美国指南在短程结核病预防疗法方面存在不足。
US Guidelines Fall Short on Short-Course Tuberculosis-Preventive Therapy.
机构信息
Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
Clin Infect Dis. 2024 Mar 20;78(3):514-517. doi: 10.1093/cid/ciad659.
Abstract
The provision of tuberculosis-preventive therapy (TPT) to vulnerable populations is critical for global control. Shorter-course TPT regimens are highly effective and improve completion rates. Despite incorporation of 1 month of rifapentine and isoniazid into global guidelines, current US TPT guidelines do not include this as a recommended regimen, but should.
摘要
为弱势群体提供结核病预防性治疗（TPT）对于全球控制至关重要。较短疗程的 TPT 方案非常有效，并提高了完成率。尽管在全球指南中纳入了利福平吡嗪酰胺 1 个月方案，但目前美国的 TPT 指南并未将其作为推荐方案，但应该这样做。
相似文献
1
US Guidelines Fall Short on Short-Course Tuberculosis-Preventive Therapy.
Clin Infect Dis. 2024 Mar 20;78(3):514-517. doi: 10.1093/cid/ciad659.
2
Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
J Int AIDS Soc. 2020 Oct;23(10):e25623. doi: 10.1002/jia2.25623.
3
One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial.
Clin Microbiol Infect. 2024 Nov;30(11):1410-1417. doi: 10.1016/j.cmi.2024.06.024. Epub 2024 Jul 10.
4
Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
Clin Infect Dis. 2024 May 15;78(5):1295-1303. doi: 10.1093/cid/ciad730.
5
Treatment of latent tuberculosis infection.
Ther Adv Respir Dis. 2013 Dec;7(6):351-6. doi: 10.1177/1753465813503028. Epub 2013 Sep 20.
6
Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
BMC Infect Dis. 2017 Feb 14;17(1):146. doi: 10.1186/s12879-017-2245-8.
7
Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0170521. doi: 10.1128/AAC.01705-21. Epub 2021 Oct 4.
8
An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
BMC Infect Dis. 2021 Jan 21;21(1):90. doi: 10.1186/s12879-021-05766-9.
9
Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting.
Clin Infect Dis. 2021 Sep 7;73(5):e1135-e1141. doi: 10.1093/cid/ciaa1835.
10
Tuberculosis Preventive Treatment.
Indian J Pediatr. 2024 Aug;91(8):823-829. doi: 10.1007/s12098-023-04969-z. Epub 2023 Dec 14.
引用本文的文献
1
Tuberculosis Infection in People Living with Human Immunodeficiency Virus: Challenges and Solutions.
Viruses. 2024 Aug 14;16(8):1295. doi: 10.3390/v16081295.
2
Acute Leukemia and Latent Tuberculosis Infection in Italy: Quantiferon-Tb Test Screening in a Low Tuberculosis Incidence Country.
Mediterr J Hematol Infect Dis. 2024 Jul 1;16(1):e2024054. doi: 10.4084/MJHID.2024.054. eCollection 2024.
本文引用的文献
1
Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis.
Lancet Glob Health. 2023 Aug;11(8):e1205-e1216. doi: 10.1016/S2214-109X(23)00251-6.
2
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
N Engl J Med. 2022 Sep 1;387(9):810-823. doi: 10.1056/NEJMoa2119430.
3
Evaluation of the Latent Tuberculosis Care Cascade Among Public Health Clinics in the United States.
Clin Infect Dis. 2022 Nov 14;75(10):1792-1799. doi: 10.1093/cid/ciac248.
4
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
MMWR Morb Mortal Wkly Rep. 2022 Feb 25;71(8):285-289. doi: 10.15585/mmwr.mm7108a1.
5
Latent Tuberculosis Infection.
N Engl J Med. 2021 Dec 9;385(24):2271-2280. doi: 10.1056/NEJMcp2108501.
6
Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
J Int AIDS Soc. 2021 Nov;24(11):e25844. doi: 10.1002/jia2.25844.
7
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400.
8
Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study.
Lancet Child Adolesc Health. 2021 May;5(5):350-356. doi: 10.1016/S2352-4642(21)00052-3. Epub 2021 Mar 24.
9
Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
J Int AIDS Soc. 2020 Oct;23(10):e25623. doi: 10.1002/jia2.25623.
10
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
Lancet HIV. 2020 Jun;7(6):e401-e409. doi: 10.1016/S2352-3018(20)30032-1. Epub 2020 Mar 30.
Zotero 插件